Cooley

Proposed Tax Legislation Would Permit Immediate Deduction of Domestic R&E Expenditures for Limited Period

June 4, 2025

On May 22, 2025, the US House of Representatives passed the "One Big Beautiful Bill Act" (OBBBA), which includes a temporary suspension of the amortization requirement for domestic research and experimentation (R&E) expenditures. Instead, the OBBBA would permit immediate deduction of certain domestic R&E expenditures in tax years beginning after December 31, 2024, and before January 1, 2030.

Historically, Section 174 of the Internal Revenue Code (IRC) permitted immediate deduction of all costs associated with R&E activities. However, as previously discussed in a May 2023 Cooley client alert, for tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 (TCJA) required taxpayers to capitalize R&E expenditures and amortize them over five years for R&E performed within the United States, or 15 years for R&E performed outside the United States. For additional background on Section 174 and the impact of the TCJA on the treatment of R&E expenditures, see this September 2023 Cooley client alert.

The capitalization requirement imposed by the TCJA eliminated immediate deduction of R&E expenditures and thereby increased taxable income for many companies in research-heavy industries, such as life sciences and software development. Many such companies, especially those with pre-commercial operations and limited sources of revenue, were surprised to have net taxable income during their research and development (R&D) phase of operations. This issue was particularly acute for life sciences companies that received upfront payments under a licensing or collaboration agreement intended to fund R&D. It had been expected that new legislation would repeal the capitalization requirement entirely and retroactively, but the proposed legislation does not do so. Instead, if it is passed into law, the OBBBA temporarily suspends the mandatory capitalization requirement for certain domestic R&E expenditures.

Under the OBBBA, new Section 174A would permit taxpayers to elect to immediately deduct R&E expenditures incurred in connection with the taxpayer's trade or business for work conducted within the United States or its possessions in taxable years beginning after December 31, 2024, and before January 1, 2030. Deductions for domestic R&E expenditures under Section 174A will be reduced by the amount of any tax credit allowed under Section 41(a) for increasing research activities.

Alternatively, new Section 174A would allow taxpayers to elect to continue to capitalize and amortize domestic R&E expenditures over a period of not less than 60 months as may be selected by the taxpayer (beginning with the midpoint of the taxable year in which such expenditures were incurred), or elect under Section 59(e) to capitalize and amortize R&E expenditures ratably over a 10-year period, beginning in the tax year in which such expenditures are incurred.

Each election made pursuant to new Section 174A would apply to all subsequent taxable years and can only be changed with the approval of the Secretary of the Treasury.

Additionally, under the OBBBA, an amendment to Section 174(d) is proposed to prevent the use of remaining tax basis associated with capitalized R&E expenditures (as either a deduction or an offset to amount realized) in the event the property developed through such expenditures is later disposed of (i.e., continued amortization of such capitalized R&E expenditures would be required even after the taxpayer disposes of the property).

Questions remain about the interaction among Section 174, 174A and other provisions of the IRC, such as the deduction for foreign-derived intangible income under IRC Section 250, global intangible low-taxed income (GILTI) and the foreign tax credit rules. It also is unclear how these proposed changes would impact anticipated guidance that is yet to be issued following the TCJA, such as the treatment of cost-sharing arrangements for research jointly conducted by affiliated entities.

If you have questions about how these changes may impact your company, we strongly suggest contacting a member of the Cooley tax team, your accountant or other tax advisor.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.

Key Contacts

Rick Jantz San Diego	rjantz@cooley.com +1 858 550 6150
Eileen Marshall Washington, DC	emarshall@cooley.com +1 202 728 7083
Amanda Pacheco Palo Alto	apacheco@cooley.com +1 650 843 5957
Aaron Pomeroy Colorado	apomeroy@cooley.com +1 720 566 4108
Jonathan Rivinus Colorado	jrivinus@cooley.com +1 720 566 4245

This information is a general description of the law; it is not intended to provide specific legal advice nor is it intended to create an attorney-client relationship with Cooley LLP. Before taking any action on this information you should seek professional counsel.

Copyright © 2023 Cooley LLP, 3175 Hanover Street, Palo Alto, CA 94304; Cooley (UK) LLP, 22 Bishopsgate, London, UK EC2N 4BQ. Permission is granted to make and redistribute, without charge, copies of this entire document provided that such copies are complete and unaltered and identify Cooley LLP as the author. All other rights reserved.